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Abstract [266 words] 
Background: Only one-third of patients with depression respond fully to antidepressant medication 
but there is little evidence regarding the best ‘next step’ treatment for those whose symptoms are 
‘treatment resistant’. The CoBalT trial examined the effectiveness of CBT as an adjunct to usual care 
(including pharmacotherapy) for primary care patients with treatment resistant depression (TRD) 
compared with usual care alone. 
Methods:  This two parallel-group multi-centre randomised controlled trial recruited 469 patients 
with TRD (on antidepressants for ≥6 weeks, Beck Depression Inventory (BDI) score ≥14 and ICD-10 
criteria for depression) from 73 UK general practices. Participants were randomised, using a 
computer generated code, to one of two groups: usual care (n = 235) or CBT in addition to usual care 
(n = 234), and were followed up for 12 months. The primary outcome was ‘response’, defined as 
≥50% reduction in depressive symptoms (BDI score) at 6 months compared to baseline. Trial 
registration was ISRCTN38231611. 
Findings: 422 participants (90%) were followed up at 6 months and 396 (84%) at 12 months. 95 
participants (46.1%) in the intervention group met criteria for ‘response’ at 6 months compared with 
46 (21.6%) in the usual care group (odds ratio (OR): 3.26 (95%CI: 2.10, 5.06) p<0.001). In repeated 
measures analyses using data from 6 and 12 months, the OR for ‘response’ was 2.89 (2.03, 4.10), 
p<0.001 and for a secondary ‘remission’ outcome (BDI score <10) was 2.74 (1.82, 4.13), p<0.001. 
Interpretation: Amongst patients who have not responded to antidepressants, CBT in addition to 
pharmacotherapy is effective in reducing depressive symptoms, and these effects, including 
outcomes reflecting remission, are maintained over 12 months.  
Funding:  NIHR HTA 
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Introduction 
Depression is a major public health problem. It is predicted to be the leading cause of disability in 
high income countries by 2030, with only HIV/AIDS and perinatal conditions ranking higher for low 
and middle income countries1.  Antidepressants are often the first-line treatment for depression and 
prescriptions for such medication have increased dramatically in recent years2;3. However, only one-
third of patients respond fully to pharmacotherapy and half do not experience at least a 50% 
reduction in depressive symptoms after 12-14 weeks of medication4. Where an adequate dose and 
duration of treatment has been given, such non-response may be termed ‘treatment resistance’. 
There is no agreed definition of treatment resistance5 but, given the extent of non-response, it is 
clear that treatment resistant depression (TRD) has a substantial impact on individuals, health 
services and society.   
 
There is no standard approach to the management of TRD. ‘Next step’ options include increasing the 
dose of pharmacotherapy, switching to a different antidepressant or augmentation with another 
pharmacological or psychological treatment. However, there is little robust evidence that these 
approaches improve outcome6;7.  
 
There is good evidence that cognitive behavioural therapy (CBT), the most widely available 
structured psychotherapy for depression, is effective for previously untreated episodes of 
depression. There has been some investigation of CBT and its variants in treating chronic and 
treatment resistant depression. The STAR*D trial evaluated a number of alternative treatment 
strategies (including switching to, or augmentation with, CBT8)  following non-response to 
medication. However, it did not include a comparison group of patients who continued on their 
existing medication; hence it is not possible to evaluate the effect of augmenting antidepressant 
medication with CBT as a ‘next step’ treatment option from STAR*D. In patients with chronic 
depression, Keller et al9 investigated a variant of CBT, cognitive behavioural analysis system of 
psychotherapy (CBASP) that puts more emphasis on behavioural and interpersonal factors than 
more traditional CBT. Keller et al9 found that combined psychotherapy and nefazodone (now 
withdrawn) was more effective than either component alone. However, a more recent trial of 
patients with chronic depression that had not responded to antidepressant medication found no 
difference in response between those who received combined treatment (CBSAP and medication) 
compared with medication alone10. 
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Limited access to psychological treatment in the UK and elsewhere has meant that, in clinical 
practice, CBT has often been reserved for those who have not responded to antidepressants. No 
large-scale randomised controlled trials (RCTs)6;7 have evaluated the effectiveness of CBT following 
non-response to pharmacotherapy compared with continuing pharmacotherapy as part of usual care 
for patients with TRD..We chose to investigate CBT rather than CBASP as there is evidence that CBT 
may reduce rates of relapse11, including amongst those with residual depressive symptoms12. 
Furthermore , some models of more persistent depression put emphasis on the cognitive rather 
than behavioural aspects of treatment13. 
 
 
The aim of the CoBalT trial was to examine the effectiveness of CBT as an adjunct to usual care 
including pharmacotherapy for primary care patients with treatment resistant depression compared 
with usual care alone. The economic evaluation will be reported separately. 
 
 
Methods 
 
Study design  
CoBalT was a multi-centre pragmatic RCT with two parallel groups14. Ethical approval was given by 
the West Midlands Research Ethics Committee (NRES/07/H1208/60) and research governance 
approval was obtained from the local Primary Care Trusts/Health Boards.  
 
Setting and Participants  
Participants were recruited from 73 general practices in urban and rural settings in three UK centres: 
Bristol, Exeter and Glasgow. Most participants were identified through a search of practice 
computerised medical records, although general practitioners (GPs) were able to refer patients 
directly to the research team. The first record search took place in November 2008 and the last 
patient was randomised in October 2010.  
 
Eligible patients were those aged 18 to 75 years who had adhered15;16 to an adequate dose (based 
on the British National Formulary (www.bnf.org.uk/bnf) and advice from psychopharmacology 
experts (Web Appendix 1)) of antidepressant medication for at least 6 weeks and had a Beck 
Depression Inventory (BDI)17 score of 14 or more. They also met ICD-10 criteria for a depressive 
episode assessed using the revised Clinical Interview Schedule (CIS-R)18;19. GPs were asked to exclude 
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patients who: (i) had bipolar disorder, psychosis or major alcohol/substance abuse problems; (ii) 
were unable to complete the questionnaires; and (iii) were pregnant. Individuals who were currently 
receiving CBT or other psychotherapy (including counselling) or secondary care for their depression, 
or who received CBT in the past three years, or who were taking part in another intervention study 
were also excluded.  
 
Recruitment 
A three-stage recruitment process was used14.  The record search identified patients who had 
received repeated prescriptions for antidepressants. Those who agreed to be contacted by the 
research team were mailed a short questionnaire that included questions about their depression 
and adherence to antidepressants. Those who met the definition of TRD (BDI score ≥14 and adhered 
to antidepressants at an adequate dose for at least 6 weeks) were contacted by telephone by a 
researcher to ascertain their eligibility with respect to current/past psychological treatment and 
current secondary care for depression. Potentially eligible patients were invited to attend a face-to-
face appointment with a researcher to discuss participating in the trial and confirm their eligibility 
(BDI score ≥14, continuing to take antidepressants at an adequate dose and fulfilling ICD-10 criteria 
for depression). Ineligible patients (and those who declined participation) were referred back to 
their GP.  
 
Randomisation, concealment of allocation and blinding 
After the collection of baseline data and obtaining written informed consent for trial participation, 
eligible patients were randomised to one of two groups: (1) usual care or (2) CBT in addition to usual 
care. Allocation was stratified by centre and minimised (with a probability weighting of 0.820) on: (i) 
baseline BDI score (14-19; 20-28; ≥29); (ii) whether the general practice had a counsellor (yes/no); 
(iii) prior treatment with antidepressants (yes/no); and (iv) duration of their current episode of 
depression (<1 year; 1-2 years; ≥2 years).  
 
Participants were taking antidepressants at the time of randomisation and were expected to 
continue with these as part of their usual care from their GP. Treatment allocation was concealed 
from the researcher through the use of an automated telephone randomisation service that was 
administered remotely and used a computer-generated code. Given the nature of the intervention it 
was not possible to blind participants, GPs, CBT therapists or researchers to the treatment 
allocation. 
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Intervention and comparator (usual care) groups 
Usual care 
There were no restrictions on the treatment options for patients randomised to be managed as 
usual by their GP. Participants could be referred for counselling, CBT or to secondary care, if it was 
clinically appropriate.  
 
Intervention 
Participants received 12 sessions of individual CBT (each lasting 50-60 minutes), with (up to) a 
further six sessions if judged to be clinically appropriate by the therapist (maximum of 18 sessions)) 
in addition to usual care from their GP. Therapy took place in the patient’s GP surgery or at nearby 
National Health Service (NHS)/University premises. Therapists used the seminal CBT for depression 
treatment manuals21;22 and, where appropriate, elaborations designed to address treatment 
resistance13. Therapists received at least 1 day of training specific to the trial from an experienced 
CBT therapist (AG) and weekly supervision from experienced CBT supervisors at each centre (GL, WK 
& CK). Therapists were flexible in responding to problems raised by the patient (e.g. by targeting 
symptoms of anxiety using appropriate cognitive behavioural models, if these were considered 
important). Emphasis was also given to formulating the psychopathology in terms of conditional 
beliefs. 
 
The intervention was delivered by 11 part-time therapists in the three sites who were representative 
of those working within NHS psychological services14. Ten out of the 11 therapists were female, their 
mean age was 39.2 years (SD 8.1) and they had practised as a therapist for a mean of 9.7 years 
(range: newly qualified to 30 years).  
 
With patient consent, therapy sessions were audio-recorded. Fidelity of the intervention to the CBT 
model was evaluated14 for a random sample of recordings by three independent raters from the 
Oxford Cognitive Therapy Centre using the Cognitive Therapy Rating scale (CTS-R), a valid and 
reliable CBT rating scale23. 
 
Follow-up 
Participants were followed up 3, 6, 9 and 12 months after randomisation14. Wherever possible, to 
maximise retention, researchers met with the participant face-to-face at 6 months and 12 months. 
Follow-ups at 3 and 9 months were conducted by telephone.  Follow-up data were collected 
between March 2009 and October 2011.  
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Outcome measures 
The primary outcome was the BDI score at 6 months, specifically a binary variable representing 
response, defined as a reduction in depressive symptoms of at least 50% compared to baseline.  
 
Secondary outcomes included the BDI score as a continuous variable, remission of symptoms (BDI 
score of less than 10), and quality of life (SF-12)24 at 6 and 12 months14. Other secondary outcomes 
at 6 and 12 months were panic25, and measures of depression (PHQ-926), and anxiety (GAD-727) used 
in psychological services28. Data on use of, and adherence to, antidepressant medication were also 
collected.  
 
Sample size  
The original sample size calculation (using nQuery 5.0) indicated that 472 participants would provide 
90% power to detect a difference of 16 percentage points in ‘response’ between the two groups 
based on a 2-sided 5% significance level and 15% loss to follow-up at 6 months. This corresponds to 
an odds ratio of 2, considered clinically important and smaller than that derived from a systematic 
review of CBT29. However, a slightly lower recruitment rate in one centre and difficulty matching 
recruitment rates to therapist capacity in two centres resulted in a revised sample size target of 432, 
which had 90% power to detect a 17 percentage point difference (30% versus 47%) in the binary 
‘response’ outcome and 87% power to detect the original difference14.  
 
Statistical Analysis 
Analysis and reporting of this trial was in accordance with Consolidated Standards of Reporting Trials 
(CONSORT) guidelines30. All analyses were undertaken in Stata 11.2, following a pre-defined analysis 
plan agreed with the Trial Steering Committee.  
 
Patient characteristics were compared at various stages of study recruitment, including using 
descriptive statistics to assess the baseline comparability of the randomised groups. The primary 
comparative analyses between the randomised groups were conducted according to the principle of 
intention-to-treat (ITT) without imputation of missing data.  Logistic regression was used to compare 
the binary primary outcome at 6 months between the groups as randomised, adjusting for study 
centre, baseline BDI score and the other three minimisation variables. Secondary analyses used 
similar regression models with additional adjustment for any variables that demonstrated marked 
imbalance at baseline and any differences in the actual time to follow-up. The analysis of other 
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secondary outcomes used linear or logistic regression as appropriate, and adjusted for any baseline 
imbalances. Repeated measures logistic and linear regression models were used to summarise the 
effect of the intervention on outcomes over 12 months. Odds ratios (OR) or differences in means, 
95% confidence intervals (95%CIs) and p values are reported.  
 
Secondary analyses used generalised latent and linear mixed models to obtain a fully specified 
heteroscedastic model31 to examine the influence of clustering by therapist.  In addition, sensitivity 
analyses examined the impact of missing data using the method of multiple imputation by chained 
equation (ice procedure version 1.9.5 dated 15 April 2011; 25 datasets ; 10 switching procedures). 
The imputation model included the variables in the primary ITT model, together with variables 
associated with missing BDI data at 6 or 12 months and other measures of depression/anxiety. 
Instrumental variable regression methods were used to estimate the Complier-Average Causal Effect 
(CACE)32 for those who were viewed as ‘on track’ to receive the full course of therapy at the time of 
the 6-month follow-up (defined as having received 9 or more sessions of CBT) and the longer-term 
12-month outcome (based on having received at least 12 sessions of CBT) for the binary ‘response’ 
(probit regression) and continuous (linear regression) BDI outcomes. (The original definition14 of a 
‘complier’ included those whose therapy goals were achieved but this was made stricter as it 
included those who had received fewer than 8 sessions.) Finally, two pre-planned subgroup analyses 
were conducted by including an interaction between treatment allocation and patient expectation of 
outcome or degree of treatment resistance (based on duration of current symptoms and past 
treatment with antidepressant medication). 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, interpretation of 
data, or writing of the paper. The corresponding author had full access to all the data in the study 
and had final responsibility for the decision to submit for publication. 
 
Results 
 
Participant flow and retention 
A detailed description of the recruitment process is outlined in Web Appendix 2 and a summary 
CONSORT diagram is presented in Figure 1. In total, 912 patients were identified as having TRD and 
invited to attend a baseline appointment, but 163 (18%) declined. There were no age or gender 
differences between those who declined and agreed to attend such an appointment (data not 
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shown), although those who agreed were more highly educated (p=0.009). At baseline, men were 
more likely to be ineligible (p=0.02) but there were no differences in age or educational background 
between those who were or were not eligible to participate in the trial (data not shown). Of the 749 
who attended a baseline appointment, 63% (n=469) were eligible to participate and gave written 
informed consent.  
  
Of those randomised, 234 were allocated to receive the intervention and 235 to continue with usual 
care from their GP. Ninety percent of participants were followed up at 6 months and 84% at 12 
months (Figure 1). Older individuals, women, those from higher socio-economic backgrounds, with 
more social support and better physical function were less likely to have missing BDI outcome data 
(data not shown). There was some evidence that those who were single, those with more severe 
depression at baseline, and those who scored more highly on measures of panic were more likely to 
have missing outcome data (data not shown).   
 
Baseline characteristics of participants 
The majority of participants were women (n=339, 72%), the mean age was 49.6 years (SD 11.7) and 
44% (n=206) were in paid employment (full/part-time). The mean BDI score at baseline was 31.8 (SD 
10.7). Twenty-eight percent (n=129) currently fulfilled ICD-10 criteria for a severe depressive episode 
and the majority (n=415, 88%) had suffered from depression in the past. The duration of the current 
episode of depression was 2 years or longer for 59% (n=276) of participants and 70% (n=327) had 
been on their current antidepressant(s) for more than 12 months. Selective Serotonin Reuptake 
Inhibitors (SSRIs) were the most common antidepressant taken at baseline (n =334) (further details 
are given in Web Appendix 3).  
 
Most participants (n=347) had a secondary diagnosis of an anxiety disorder according to the CIS-R 
(generalised anxiety: n=245; panic disorder: n=67; phobias: n=35). Forty-three percent (n=202) of 
participants reported another longstanding illness or disability (diabetes, asthma, arthritis, heart 
disease, high blood pressure or lung disease). 
 
Amongst those randomised, the intervention group included more men, more individuals in paid 
employment and more who reported financial difficulty, fewer individuals with caring 
responsibilities or longstanding illness/disability and better physical function (SF-12) (Table 1). A 
smaller proportion of those in the intervention group had taken their current antidepressants for 
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more than 12 months and they were less likely to have experienced 5 or more prior episodes of 
depression, although a greater proportion had a family history of depression.  
 
Delivery and receipt of the intervention 
Nine of the 11 therapists delivered 97% of the intervention and, for these, the number of patients 
per therapist ranged from 13 (5.6%) to 41 (17.5%). The mean CTS-R rating (adjusted for caseload) 
based on a random sample of 54 sessions was 38.8 (95%CI: 36.7, 40.8) which is above the threshold 
of competence expected in UK CBT training programmes.  
 
The average duration of the intervention (from randomisation) was 6.3 months (SD 3.0). Twenty 
participants (8.5%) did not attend any therapy sessions. In total, 74 participants (31.6%) either 
withdrew from therapy (n=47) or were discharged having repeatedly not attended appointments 
(n=27). The number withdrawing increased to 70 if those participants who reached an ‘agreed end’ 
in less than 12 sessions were included. 
 
 By 6 months, those randomised to the intervention had received a median of 11 sessions of CBT 
[IQR: 5, 13] and 62% (n=144) had received at least 9 sessions. By 12 months, the median was 12 
[IQR: 6, 17] and 141 participants had received at least 12 sessions.  
 
Primary outcome – ‘response’ at 6 months 
Those in the intervention group had a three-fold increased odds of ‘response’ at 6 months compared 
with those in the usual care group (Table 2). Adjustment for imbalances at baseline had little effect, 
if anything slightly increasing the estimated effect, and adjustment for the actual time to follow-up 
did not affect the findings (data not shown). The difference in proportions ‘responding’ equated to a 
number needed to treat (NNT) of 4 (95%CI: 3, 6) for each additional ‘responding’ patient.  
 
Secondary outcomes at 6 months 
The beneficial effect of the intervention was confirmed for the secondary outcomes at 6 months 
(Table 2). Those in the intervention group had a BDI score that was, on average, 5.7 points lower 
(less depressed) than those in the usual care group, which equated to an effect size of 0.53 using 
baseline SD for BDI (pooled).  Those in the intervention group were also more likely to experience 
‘remission’ (BDI score<10) at 6 months (NNT 8 (95%CI: 5, 20)), to have fewer symptoms of anxiety 
(GAD-7) and panic at 6 months and had greater improvements in the SF-12 mental health subscale 
(Table 2). There was weak evidence that those in the intervention group fared worse on the SF-12 
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physical subscale, but the difference was small and the 95%CI included the null (Table 2). 
Adjustment for baseline imbalances did not affect any of these findings (data not shown).  
 
Secondary analyses for the primary outcome 
There was little evidence of clustering of outcomes by therapist (intracluster correlation coefficient 
for continuous BDI score, after adjustment for baseline, was 0.0027). In a fully heteroscedastic 
model that accounted for clustering by therapist, the results obtained for the primary ‘response’ 
outcome were identical to those obtained from the primary ITT analysis (data not shown). The 
results imputing missing data were consistent with the findings of the primary ‘complete-case’ 
analysis (Table 3). Regarding a priori subgroup analyses, there was no evidence that patient 
expectation of outcome or degree of treatment resistance had any effect on the difference between 
intervention and usual care groups (p value for interaction: 0.16 and 0.88 respectively). In a post-hoc 
sub-group analysis, there was no evidence that study centre had any effect on the difference 
between the intervention and usual care groups (p value for interaction between treatment 
allocation and centre: 0.61).  
 
Outcomes over 12 months 
In repeated measures analyses using data from 6 and 12 months, those in the intervention group 
had a three-fold increased odds of response and remission over the 12 months (Table 4). There was 
little evidence that the effect of the intervention varied over time (p value for interactions >0.10), 
with the exception of the outcomes on the PHQ-9 and SF-12 physical sub-scale where there was 
weak evidence for an interaction (p =0.059 and p=0.047 respectively).  
 
Treatment efficacy 
Compared with the ITT models in Table 2, the estimates of treatment efficacy obtained from CACE 
analyses demonstrated that the effect of the intervention was larger amongst those who were ‘on 
track’ at 6 months to complete the intervention, and likewise among those who received at least 12 
sessions by 12 months. At 6 months the CACE estimate for the continuous BDI outcome was -8.2 
(95%CI: -11.4, -5.0), and at 12 months -7.1 (95%CI: -10.4, -3.8) (effect size 0.77 and 0.66 respectively; 
both p<0.001). Larger effects were also observed for the binary outcomes using probit regression 
(data not shown).  
 
Of 388 participants with data at 6 and 12 months, 66 participants (17%) had at least one session of 
‘talking therapy’ outwith the trial during the 12 months (usual care: n = 41 (21.0%); intervention: 25 
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(13.0%)). Only 5 participants (3 usual care; 2 intervention) had received at least 12 sessions of CBT 
outwith the trial by 12 months. Estimates of treatment efficacy accounting for contamination by the 
receipt of such CBT were identical (data not shown). 
 
Use of, and adherence to, antidepressants over the study 
At 6 months, 93% of both groups were taking antidepressant medication (difference: -0.6% (95%CI: -
5.4, 4.2)). At 12 months, 88% of those in the intervention group were taking antidepressants 
compared with 92% of those randomised to usual care (difference: -4.5% (95%CI: -10.4, 1.3)). Of the 
354 participants with self-report data on the type and dose of antidepressant medication taken at 12 
months, 154 (43.5%) reported taking a different type or dose of medication from that at baseline 
(intervention group: n = 76 (44.2%); usual care group: n = 78 (42.9%)). 
 
Of those taking antidepressants at 6 months, 92% of the intervention group and 88% of those in 
usual care had adhered to their medication over the previous 6 weeks. The comparable figure at 12 
months for both groups was 93%.  
 
Discussion  
 
CBT as an adjunct to usual care that included pharmacotherapy was effective in reducing depressive 
symptoms and improving quality of life in primary care patients with TRD. The beneficial effect of 
the intervention was also observed for the more stringent criteria of ‘remission’ and improvements 
were maintained over 12 months. 
 
There is no single accepted definition of TRD, hence we used an inclusive and pragmatic definition 
that would be generalisable to primary care33. Participants had not responded to at least 6 weeks 
treatment with an antidepressant; however, this was a heterogeneous group with many reporting 
chronic depression often associated with psychological and/or physical co-morbidities.  The mean 
BDI score was 31.8, 29% of participants had severe depression at baseline according to ICD-10 
criteria, and most had a past history of depression, with the majority reporting at least five previous 
episodes. Hence, we think that the results are generalisable to a wide range of patients who have 
not responded to antidepressants.  
 
Prior to this study, there was no evidence from large-scale RCTs on the effectiveness of CBT as an 
adjunct to pharmacotherapy as a ‘next step’ treatment option for primary care patients who had not 
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responded to antidepressants6;7. Recent trials (including our pilot34) were small (n<50)35;36.   In the 
STAR*D study , only 26% of participants were willing to be randomised to CBT as a second-step 
option8 and individuals who could not tolerate citalopram were included, making extrapolation 
difficult as clinically such individuals would usually be managed by a change of antidepressant. Like 
CoBalT, many participants in the CBT augmentation group of STAR*D (n = 65) had a history of 
depression (86%), with an average of seven prior episodes8. Thirty-five percent of STAR*D 
participants whose medication was augmented by CBT fulfilled criteria for response based on self-
rated depressive symptoms8, slightly lower than our findings using the BDI (46.1%), although 
remission rates were similar. However, STAR*D8 and other studies35;36 answered a different question 
than that posed in CoBalT. They provide evidence on alternative treatment approaches to the 
management of those who do not respond to antidepressants, rather than examining the 
effectiveness of augmenting antidepressant medication with CBT as a ‘next step’ option.  
 
The effects observed are comparable to the findings of an earlier RCT of combined psychological 
(CBASP) and pharmacological treatment for chronic depression9. However, the more recent REVAMP 
trial of a similar population who had not responded to antidepressant medication found no 
difference in response after 12 weeks between those who received combined treatment compared 
with medication alone10.In the latter, participants attended fewer sessions of CBASP than for the 
earlier chronic depression trial9 (mean: 12.5 vs. 16), which may contribute to explaining the differing 
findings. CBASP and the more ‘traditional’ CBT delivered in CoBalT differ in terms of emphasis. The 
Beckian CBT approach adapted by Moore and Garland13 and used in CoBalT emphasises the cognitive 
elements of treatment and has also been shown to be effective in those with residual depression12.  
 
In the REVAMP trial, a treatment algorithm was used and pharmacotherapy changed to the ‘next-
step’ following randomisation10. However, the use of a medication algorithm is not a pragmatic 
approach towards pharmacotherapy. There was a higher remission rate amongst those receiving 
pharmacotherapy in REVAMP (38.5% at 12 weeks) compared with CoBalT (15.0% for the usual care 
group at 6 months), but this may relate to differences in the patients recruited. Only 33% of REVAMP 
participants had previously had an adequate trial of pharmacotherapy, whereas 80% of CoBalT 
participants had previously been prescribed antidepressants and most (70%) had been on their 
current medication for more than 12 months.  
 
Strengths and limitations of the study 
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This was a large study with high follow-up rates at 6 and 12 months. There was no evidence that 
missing data had biased findings. Though there were some imbalances in baseline characteristics, 
between the randomised groups, if anything, adjusting for these increased the size of the treatment 
effect for the primary outcome. Only a minority of participants received CBT outwith the trial so 
such contamination had little impact on the findings. 
 
We did not compare CBT with an “attention” control as we wanted to ask a pragmatic question 
about the value of adding CBT to antidepressants in this population.  This meant we could not blind 
patients or researchers to the treatment allocation but we avoided observer bias by using self-report 
questionnaires to measure outcome.  Our primary outcome was depressive symptoms on the BDI. 
This instrument was also used by the therapists within CBT sessions; hence, for those in the 
intervention group, the responses on this specific measure may have been influenced by the process 
of therapy.  However, results were consistent for the other mental health outcomes (that were not 
used in therapy), including for the PHQ-9, which is part of the core outcome dataset within UK 
psychological services28. 
 
An independent evaluation confirmed that the therapy was delivered at a ‘competent’23 standard.  
The therapists were broadly representative of those working in NHS psychological services with a 
range of experience and backgrounds and thus the results should therefore be generalisable.  There 
was no evidence of any clustering of outcomes by therapist.  
 
We relied on a self-report measure of adherence to medication15 that had been validated against 
electronic monitoring bottles16 in order to define our population with TRD. Whilst some of those 
recruited may not have adhered to their medication (‘false positives’), the vast majority had, at 
baseline, been on their current antidepressant for more than 12 months, which is likely to minimise 
the effect of occasional non-adherence.  
 
Implications for practice and directions for future research 
A substantial proportion of people do not respond to antidepressants and our results have provided 
robust evidence that CBT given as an adjunct to usual care that includes antidepressant medication 
is an effective treatment in reducing depressive symptoms and improving quality of life in this 
population.  The size of the treatment response was substantial and of clinical importance and was 
maintained at the 12 month follow-up after the CBT treatment had ended.  Given the chronic 
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relapsing nature of depression, it would be important to examine the long-term outcome of this 
intervention.  
 
Though we did not test different approaches towards the delivery of CBT we think that the complex 
mental health needs of this population require therapists who are able to tailor the treatment 
approach to the individual and formulate conditional beliefs that, according to cognitive theory13;21, 
underpin the longer term risk of depression.  This kind of therapy would be delivered by  “high 
intensity” services in England28 (http://www.iapt.nhs.uk/) and requires both training and regular 
supervision.   
 
In many countries, access to psychological treatment is limited to those who can afford to pay, or 
those with health insurance, and amongst the latter, cost-sharing through co-payment is common. 
Increasing the availability of CBT is more difficult than providing an intervention such as 
pharmacotherapy. There have been recent initiatives to increase access to psychological therapies in 
England28 (IAPT: http://www.iapt.nhs.uk/) and Australia ( http://www.health.gov.au/mentalhealth-
betteraccess/).  The IAPT scheme, for example, has provided training and set minimum standards of 
competencies and supervision in order to provide a consistent standard of care. Worldwide, such 
initiatives are rare and more investment is needed. In the United States, less than a quarter of those 
with depression have seen a psychologist or counsellor in the previous 12 months37, and half receive 
less than the recommended number of therapy sessions38.  Even those who attend therapy often 
receive an “eclectic mix of psychotherapy techniques”39 rather than CBT. Only through greater 
investment in psychological services that deliver evidence-based therapies will it be possible to 
reduce the significant burden to patients, health care systems and society that is associated with 
non-response to the most common first-line treatment for depression in primary care. 
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Panel: Research in context  
Systematic Review 
Systematic reviews of psychological interventions for treatment resistant depression have found no 
large-scale high quality trials of CBT as an adjunct to pharmacotherapy as a ‘next step’ treatment 
option compared with continuing pharmacotherapy as part of usual care6;7. Using search terms 
based on these reviews, we identified three trials that have been published subsequently. One of 
which was our pilot study (n=25) for this RCT34, the second (n=44) examined augmentation with CBT 
amongst partial responders to antidepressants35 and the third study (n=36) of inpatients was 
published only as a conference abstract36. Neither of the latter two studies included a group who 
remained on antidepressants in order to evaluate the effectiveness of CBT as an adjunct to 
antidepressant medication (comparators: lithium augmentation35; and augmentation with 
supportive therapy36). 
Interpretation 
The results of this large-scale multi-centre trial are useful in informing the ‘next step’ treatment for 
those who do not respond to antidepressant medication. CBT given as an adjunct to usual care that 
included antidepressant medication was found to be an effective treatment in reducing depressive 
symptoms and improving quality of life over 12 months compared with usual care alone for primary 
care patients with treatment resistant depression.  
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Figure 1 – Trial CONSORT flowchart 
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Table 1 – Baseline comparability of randomised groups 
 Intervention 
(n = 234) 
Usual care 
(n = 235) 
Stratification variable: Centre n (%)     
Bristol 95 (40.6%) 95 (40.4%) 
Exeter 79 (33.8%) 82 (34.9%) 
Glasgow 60 (25.6%) 58 (24.7%) 
     
Minimisation variables: n (%)     
Previously prescribed antidepressants  187 (79.9%) 190 (80.9%) 
     
BDI score      
14-19 24 (10.3%) 28 (11.9%) 
20-28 78 (33.3%) 75 (31.9%) 
≥29 132 (56.4%) 132 (56.2%) 
     
GP practice has a counsellor 112 (47.9%) 116 (49.4%) 
     
Duration of current episode of depression     
<1 year 58 (24.8%) 52 (22.1%) 
1-2 years 40 (17.1%) 43 (18.3%) 
> 2 years 136 (58.1%) 140 (59.6%) 
     
Socio-demographic variables     
Age (years): mean (SD) 49.2 yrs (11.9) 50.0 
yrs 
(11.5) 
     
Female: n (%) 161 (68.8%) 178 (75.7%) 
     
Ethnic group – White: n (%) 231 (98.7%) 228 (97.0%) 
     
Marital status: n (%)     
Married/living as married 120 (51.3%) 128 (54.5%) 
Single 44 (18.8%) 45 (19.2%) 
Separated/Divorced/Widowed 70 (29.9%) 62 (26.4%) 
     
Employment status: n (%)     
In paid employment (full/part-time) 109 (46.6%) 97 (41.3%) 
Not in employment  58 (24.8%) 75 (31.9%) 
Unemployed due to ill health 67 (28.6%) 63 (26.8%) 
     
Highest educational qualification: n (%) *     
A level, Higher grade or above 112 (48.3%) 105 (45.5%) 
GCSE, Standard grade or other  63 (27.2%) 67 (29.0%) 
No formal qualifications 57 (24.6%) 59 (25.5%) 
     
Financial difficulty: n (%)     
Living comfortably/doing alright 74 (31.6%) 93 (39.6%) 
Just about getting by 91 (38.9%) 83 (35.3%) 
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Finding it difficult/v.difficult to make ends meet 69 (29.5%) 59 (25.1%) 
     
Caring responsibilities 29 (12.4%) 35 (14.9%) 
     
Long-standing illness or disability 170 (72.7%) 181 (77.0%) 
     
Number of life events in past 6 months: mean (SD) 1.3 (1.2) 1.2 (1.1) 
     
Social support score: mean (SD) 11.8 (3.9) 12.2 (3.7) 
     
History of depression     
Suffered from depression in past 206 (88.0%) 209 (88.9%) 
     
Number of prior episodes of depression      
0-1 46 (19.7%) 45 (19.2%) 
2-4 72 (30.8%) 61 (26.0%) 
≥5 116 (49.6%) 129 (54.9%) 
     
Previous referral to a psychiatrist for depression 95 (40.6%) 93 (39.6%) 
     
Family history of depression 159 (68.0%) 148 (63.0%) 
     
Length of current course of antidepressants     
<6 months 26 (11.1%) 23 (9.8%) 
6 – 12 months 51 (21.8%) 42 (17.9%) 
>12 months 157 (67.1%) 170 (72.3%) 
     
CIS-R score: mean (SD) 30.1 (9.1) 30.0 (8.8) 
     
ICD-10 primary diagnosis: n (%)     
Mild 35 (15.0%) 31 (13.2%) 
Moderate 135 (57.7%) 139 (59.2%) 
Severe 64 (27.4%) 65 (27.7%) 
     
BDI score: mean (SD) 31.8 (10.5) 31.8 (10.9) 
Suicidal ideation (CIS-R thoughts/plans): n (%) 73 (31.1%) 75 (31.9%) 
     
PHQ-9 score: mean (SD) 16.6 (5.7) 16.6 (5.7) 
GAD-7 score: mean (SD) 11.7 (5.0) 11.8 (5.1) 
Panic score: median [IQR]† 3 [0, 5] 3 [0, 5] 
     
SF-12 mental subscale: mean (SD)‡ 28.5 (9.0) 28.7 (9.3) 
SF-12 physical subscale: mean (SD) ‡ 45.3 (13.0) 41.6 (13.7) 
Incomplete data on some items, numbers with information available as listed:  
*CBT n = 232, UC n = 231; †CBT n = 233, UC n = 235; ‡CBT n = 231, UC n = 233 
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Table 2 – Intention-to-treat analyses of primary and secondary outcomes at 6 month follow-up 
 Intervention Usual care Adjusted OR 
or adjusted 
difference in 
means* 
95%CI p value Effect size 
for 
continuous 
outcomes† 
N n or 
Mean 
% or SD N n or 
Mean 
% or SD 
Primary outcome           
Response 206 95 (46.1) 213 46 (21.6) 3.26 (2.10, 5.06) <0.001 - 
Secondary outcomes           
BDI score 206 18.9 (14.2) 213 24.5 (13.1) -5.7 (-7.9, -3.4) <0.001 0.53 
Remission (BDI<10) 206 57 (27.7) 213 32 (15.0) 2.30 (1.39, 3.81) 0.001 - 
PHQ-9 209 9.5 (6.7) 213 12.5 (6.6) -3.0 (-4.2, -1.8) <0.001 0.53 
GAD-7 207 7.0 (5.9) 213 9.5 (5.6) -2.5 (-3.4, -1.5) <0.001 0.49 
Panic 205 1.6 (2.1) 213 2.1 (2.2) -0.6 (-1.0, -0.3) 0.001 0.26 
SF-12 mental subscale 201 39.1 (14.1) 209 33.7 (12.6) 5.8 (3.5, 8.2) <0.001 0.63 
SF-12 physical subscale 201 44.1 (14.2) 209 42.1 (14.0) -1.6 (-3.3, 0.05) 0.057 0.12 
*ITT analysis adjusted for baseline measure of the outcome and the stratification (centre) and minimisation variables (BDI score, previously prescribed antidepressants, whether the GP 
practice has a counsellor and duration of current episode of depression) 
†Effect size based on pooled SD of baseline measure 
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Table 3 – Sensitivity analyses of the primary and secondary BDI outcomes at 6 months including imputed data for those with missing BDI outcome data 
 N Adjusted OR 
or adjusted 
difference in 
means* 
95%CI p value 
Response at 6 months 469 3.10 (2.00, 4.80) <0.001 
BDI score at 6 months 469 -5.5 (-7.8, -3.3) <0.001 
Remission at 6 months 469 2.34 (1.43, 3.85) <0.001 
*Adjusted for baseline BDI score and the stratification (centre) and other minimisation variables (previously prescribed antidepressants, whether the GP practice has a 
counsellor and duration of current episode of depression) 
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Table 4 – Intention-to-treat repeated measures analyses of outcomes at 6 and 12 month follow-up 
 Intervention Usual care Repeated measures analyses 
N n or Mean at 
12 months 
% or SD N n or Mean at 
12 months 
% or SD N Adjusted OR 
or adjusted difference 
in means* 
95%CI p value 
Response 197 109 (55.3) 198 62 (31.3) 814 2.89 (2.03, 4.10) <0.001 
BDI score 197 17.0 (14.0) 198 21.7 (12.9) 814 -5.1 (-7.1, -3.1) <0.001 
Remission (BDI<10) 197 78 (39.6) 198 36 (18.2) 814 2.74 (1.82, 4.13) <0.001 
PHQ-9† 197 9.0 (7.0) 198 10.9 (6.4) 1196 -2.8 (-3.7, -1.8) <0.001 
GAD-7 197 6.7 (6.2) 198 8.5 (5.8) 815 -2.2 (-3.0, -1.3) <0.001 
Panic 195 1.5 (2.1) 198 1.7 (2.2) 811 -0.5 (-0.8, -0.2) 0.001 
SF-12 mental subscale 194 39.1 (14.6) 195 35.4 (12.8) 799 4.8 (2.7, 6.9) <0.001 
SF-12 physical subscale 194 44.6 (13.2) 195 41.1 (13.5) 799 -0.7 (-2.1, 0.8) 0.35 
*ITT analysis adjusted for baseline measure of outcome and the stratification (centre) and minimisation variables (BDI score, previously prescribed antidepressants, whether the GP practice 
has a counsellor and duration of current episode of depression) 
†Data on PHQ-9 were available at three time points (6, 9 and 12 months): mean (SD) at 9 months: intervention: n=188, 8.8 (6.9); usual care: n=191, 12.0 (6.2) 
 
 
 
 
 
 
